Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors
Gregory R. Pond, Archana M. Agarwal, Moshe Chaim Ornstein, Jorge García, Ruby Gupta, Petros Grivas, Alexandra Drakaki, Jae‐Lyun Lee, Ravindran Kanesvaran, Giuseppe Di Lorenzo, Pasquale Verolino, Pedro C. Barata, Mehmet Asım Bilen, Syed A. Hussain, Catherine Curran, Guru Sonpavde
Topics & Concepts
MedicineNivolumabInternal medicinePembrolizumabDurvalumabOncologyAtezolizumabMetastatic Urothelial CarcinomaCarboplatinCisplatinResponse Evaluation Criteria in Solid TumorsRetrospective cohort studyUrologyBladder cancerUrothelial carcinomaCancerChemotherapyProgressive diseaseImmunotherapyBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis